Blood Sugar Regulation, Anthocyanins, and Metabolic Health

Evidence Review

Randomized Controlled Trial: Dose-Finding in Borderline Diabetes (Thaipitakwong et al., 2020)

This RCT (PMID 32147046) enrolled obese adults with borderline diabetes to determine the optimal dose of mulberry leaf DNJ and assess safety over 12 weeks. Participants were randomized to receive 12 mg, 18 mg, or 36 mg of DNJ per day (delivered as mulberry leaf extract, three divided doses with meals) or placebo. The primary endpoints were fasting plasma glucose and 2-hour postprandial glucose [1].

All three active doses produced statistically significant reductions in postprandial glucose compared to baseline and placebo. The 12 mg/day dose showed a mean postprandial glucose reduction of approximately 18 mg/dL; the 36 mg/day dose showed approximately 32 mg/dL reduction. Fasting glucose fell significantly in the 18 mg and 36 mg groups. No dose-limiting adverse effects were observed, and liver and kidney function markers remained normal throughout. The authors concluded that 12 mg DNJ/day represented an effective and well-tolerated minimum dose, with additional but diminishing benefit at higher doses.

Strengths: randomized, controlled, dose-ranging design with a clinically relevant population (borderline diabetes with obesity, a group at high short-term conversion risk to type 2 diabetes). Limitations: modest sample size, single center, and a 12-week window is insufficient to assess long-term HbA1c changes or durability of effect.

Randomized Controlled Pilot Study: Type 2 Diabetes (Riche et al., 2017)

This placebo-controlled pilot trial (PMID 28619294) evaluated mulberry leaf extract in adults with established type 2 diabetes over 30 days. Participants received either mulberry leaf extract (1000 mg three times daily, standardized preparation) or placebo alongside their usual antidiabetic medications [2].

The mulberry group showed a trend toward reduced HbA1c and fasting glucose versus placebo, though the pilot's small sample size (n=21 completers) meant results did not reach statistical significance on all endpoints. Post-hoc analysis suggested a meaningful effect in participants who were not using metformin concurrently — raising the possibility that metformin's own alpha-glucosidase effects may overlap with and partially mask mulberry's contribution. No serious adverse events were recorded.

This trial is valuable primarily as a safety and feasibility study rather than a definitive efficacy demonstration. The absence of significant toxicity in a medicated diabetic population supports the safety profile, and the mechanistic hypothesis about metformin interaction is worth exploring in larger studies.

Meta-Analysis: Blood Glucose and Lipid Effects of Morus alba (Phimarn et al., 2017)

This meta-analysis (PMID 26972284), published in the European Journal of Nutrition, pooled data from multiple randomized and controlled trials examining Morus alba preparations across different populations and formulations. Aggregate analysis found statistically significant reductions in:

• Fasting blood glucose: mean reduction of −14.8 mg/dL (weighted mean difference, 95% CI crossing zero in some subgroups, significant in the pooled analysis)
• LDL cholesterol: modest but significant reduction
• Triglycerides: significant reduction, particularly in studies using higher doses
• Total cholesterol: modest reduction [3]

HDL cholesterol showed a non-significant trend toward improvement. The authors noted considerable heterogeneity across studies in preparation type (leaf powder, standardized extract, tea), dose, and population (healthy, prediabetic, diabetic), which limits the precision of the pooled estimates. The overall conclusion was that Morus alba preparations appear modestly effective for both glycemic and lipid outcomes, with a favorable safety profile across trials, but that larger and more standardized trials are needed.

Mechanistic Review: Metabolic Disease Applications (Zhang et al., 2022)

This comprehensive review (PMID 34896248) in Pharmacological Research summarized preclinical and clinical evidence for mulberry leaf's mechanisms across diabetes, dyslipidemia, obesity, atherosclerosis, and hypertension. The review identified DNJ-mediated alpha-glucosidase inhibition as the primary mechanism for postprandial glucose control, but also documented [4]:

• Chlorogenic acid effects: Improve insulin receptor signaling and GLUT4 translocation in skeletal muscle; reduce hepatic glucose output via AMPK activation
• Rutin and quercetin: Inhibit protein tyrosine phosphatase 1B (PTP1B), which normally dampens insulin signaling, thereby sensitizing cells to insulin
• Polysaccharides: Mulberry leaf polysaccharides activate AMPK and improve glycogen synthesis in liver and muscle
• Moranoline (DNJ) cardiovascular effects: Beyond glucose, DNJ has been shown to reduce atherosclerotic lesion development in animal models by improving lipid profiles and reducing oxidative modification of LDL

The review concluded that mulberry leaf's polypharmacological profile — multiple bioactives acting on complementary metabolic pathways — may explain why its clinical effects span both glycemic and lipid outcomes.

Antioxidant Properties of Mulberry Fruit (Ajay Krishna et al., 2018)

This study (PMID 29576709), published in Pharmacognosy Magazine, characterized the antioxidant and hemolysis-protective effects of polyphenol-rich mulberry fruit extract. The extract demonstrated DPPH radical scavenging activity (IC50 of 89.2 μg/mL), ABTS radical scavenging, ferric-reducing antioxidant power (FRAP), and significant protection against oxidative hemolysis of red blood cells at physiologically relevant concentrations [5].

The total phenolic content was measured at approximately 48.2 mg gallic acid equivalents per gram of extract, and anthocyanin content was among the highest reported for common edible berries in the comparison data cited. The study identified cyanidin-3-glucoside and cyanidin-3-rutinoside as the dominant anthocyanins — the same compounds found in black elderberry, which has stronger name recognition but a comparable phenolic profile.

Lifespan and Cellular Protection via Nrf2/MAPK (Yan et al., 2017)

This study (PMID 28713491) investigated mulberry anthocyanin extract (MAE) in HepG2 liver cells exposed to hydrogen peroxide (an oxidative stress model) and in Caenorhabditis elegans (a standard lifespan model). In HepG2 cells, MAE dose-dependently reduced oxidative damage markers (ROS, malondialdehyde, protein carbonyls) and increased superoxide dismutase and catalase activity via activation of the Nrf2 pathway. In C. elegans, supplementation with MAE at 400 μg/mL extended mean lifespan by approximately 15% compared to control animals, a modest but consistent effect across replicate experiments [6].

The MAPK signaling data suggested that MAE activates the p38 pathway, which upregulates stress resistance genes. While nematode lifespan data do not translate directly to human aging, the mechanistic demonstration of Nrf2 activation is relevant: Nrf2 is a validated target for reducing chronic oxidative stress in humans, and several evidence-supported dietary compounds (sulforaphane, curcumin) work via this pathway. Mulberry anthocyanins appear to be members of this functional category.

Evidence Strength Summary

The glycemic effects of mulberry leaf are among the better-documented of any non-pharmacological botanical intervention. Two randomized controlled trials, a meta-analysis of pooled trial data, and a mechanistically well-characterized active compound (DNJ) provide a coherent evidentiary case. The main gaps are the absence of large multicenter trials, limited long-term safety data beyond 12 weeks, and the need for studies that better characterize effects in populations not taking concurrent antidiabetic medication.

The antioxidant and lipid evidence is solid mechanistically but relies more heavily on in vitro and animal data, with the meta-analysis providing the strongest indication that real-world lipid benefits accompany glycemic improvement. Mulberry fruit, used as a food, represents a low-risk, nutritionally positive addition to the diet. Mulberry leaf extract is a reasonable evidence-based option for people specifically targeting postprandial blood sugar, approached with appropriate care around interactions with antidiabetic medication.